ArticleEuropean journal of nuclear medicine and molecular imaging2011
In vivo ¹⁸F-FDG tumour uptake measurements in small animals using Cerenkov radiation.
Article in European journal of nuclear medicine and molecular imaging, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 89 citations in OpenAlex.
- Cerenkov luminescence microscopy: A novel approach for high-resolution radiotracer imaging.iScience · 2025Article
- Prospective testing of clinical Cerenkov luminescence imaging against standard-of-care nuclear imaging for tumour location.Nature biomedical engineering · 2022Observational
- Surgical Advances in Osteosarcoma.Cancers · 2021Review
- Imaging techniques in nanomedical research.European journal of histochemistry : EJH · 2020Article
- Radionuclide-Activated Nanomaterials and Their Biomedical Applications.Angewandte Chemie (International ed. in English) · 2019Review
- Innovations in Nuclear Imaging Instrumentation: Cerenkov Imaging.Seminars in nuclear medicine · 2018Review
- Cerenkov luminescence imaging: physics principles and potential applications in biomedical sciences.EJNMMI physics · 2017Review
- Quantitative Measurement of the Thyroid Uptake Function of Mouse by Cerenkov Luminescence Imaging.Scientific reports · 2017Article
- Utilizing the power of Cerenkov light with nanotechnology.Nature nanotechnology · 2017Review
- Cerenkov Luminescence Imaging as a Modality to Evaluate Antibody-Based PET Radiotracers.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2017Article
- Theranostic Role ofTheranostics · 2017Article
- Recent Advances of Light-Mediated Theranostics.Theranostics · 2016Review
- Cherenkov radiation fluence estimates in tissue for molecular imaging and therapy applications.Physics in medicine and biology · 2015Article
- Unified approach for bioluminescence, Cerenkov, β, X and γ rays imaging.Biomedical optics express · 2015Article
- Feasibility study of novel endoscopic Cerenkov luminescence imaging system in detecting and quantifying gastrointestinal disease: first human results.European radiology · 2015Article
- Ultrahigh-resolution Cerenkov-light imaging system for positron radionuclides: potential applications and limitations.Annals of nuclear medicine · 2014Article
- Performance evaluation of endoscopic Cerenkov luminescence imaging system: in vitro and pseudotumor studies.Biomedical optics express · 2014Article
- Probability method for Cerenkov luminescence tomography based on conformance error minimization.Biomedical optics express · 2014Article
- Cerenkov imaging.Advances in cancer research · 2014Review
- Optimization of microfluidic PET tracer synthesis with Cerenkov imaging.The Analyst · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose2-[(18)F]Fluoro-2-deoxy-D-glucose ((18)F-FDG) is a widely used PET radiotracer for the in vivo diagnosis of several diseases such as tumours. The positrons emitted by (18)F-FDG, travelling into tissues faster than the speed of light in the same medium, are responsible for Cerenkov radiation (CR) emission which is prevalently in the visible range. The purpose of this study is to show that CR escaping from tumour tissues of small living animals injected with (18)F-FDG can be detected with optical imaging (OI) techniques using a commercial optical instrument equipped with charge-coupled detectors (CCD).
methodsThe theory behind the Cerenkov light emission and the source depth measurements using CR is first presented. Mice injected with (18)F-FDG or saline solution underwent dynamic OI acquisition and a comparison between images was performed. Multispectral analysis of the radiation was used to estimate the depth of the source of Cerenkov light. Small animal PET images were also acquired in order to compare the (18)F-FDG bio-distribution measured using OI and PET scanner.
resultsCerenkov in vivo whole-body images of tumour-bearing mice and the measurements of the emission spectrum (560-660 nm range) are presented. Brain, kidneys and tumour were identified as a source of visible light in the animal body: the tissue time-activity curves reflected the physiological accumulation of (18)F-FDG in these organs. The identification is confirmed by the comparison between CR and (18)F-FDG images.
conclusionThese results will allow the use of conventional OI devices for the in vivo study of glucose metabolism in cancer and the assessment, for example, of anti-cancer drugs. Moreover, this demonstrates that (18)F-FDG can be employed as it is a bimodal tracer for PET and OI techniques.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.